We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

TCF Theracryf Plc

0.025 (2.70%)
Last Updated: 13:47:18
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Theracryf Plc LSE:TCF London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.025 2.70% 0.95 0.90 1.00 0.95 0.925 0.925 8,950,841 13:47:18
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 422k -4.04M -0.0147 -0.65 2.61M

Theracryf PLC Total Voting Rights

02/05/2024 7:00am

RNS Regulatory News

RNS Number : 9121M
Theracryf PLC
02 May 2024

TheraCryf plc

("TheraCryf", the "Company" or the "Group")


Total Voting Rights


Alderley Park, UK - 2 May 2024:  In accordance with Disclosure Guidance and Transparency Rule 5.6.1, the Company would like to notify the market that as of 30 April 2024, the total number of Ordinary Shares in issue is 427,346,895, with no shares held in treasury. This is the figure that may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.


- Ends -


TheraCryf plc
Dr Huw Jones, CEO 
Toni Hänninen, CFO

Dr Helen Kuhlman, CBO

+44 (0)1625 315 090

Cavendish Capital Markets (NOMAD and Broker)
Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance)
Nigel Birks /
Harriet Ward (ECM)

+44 20 7220 0500

Instinctif Partners

Melanie Toyne-Sewell / Jack Kincade

+44 207 457 2020


About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on oncology and neuropsychiatry. The Company has a broad clinical and preclinical pipeline in indications such as neurodevelopmental disorders, glioblastoma*, addiction, anxiety and narcolepsy* [*orphan indications]. Its strategy is to generate compelling data sets to proof of concept and/or later phase II to partner its clinical programmes with mid-size to large pharma. As well as a number of industry partnerships with companies, including Stalicla, in neurodevelopment disorders and has sourced programmes from companies such as Takeda and Shire, the Company has worked with and has ongoing collaborations with major universities, hospitals and government organisations such as the University of Manchester, Sapienza (Università di Roma), Kings College London and University of Connecticut.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is listed on AIM in London and trades under the ticker symbol TCF. 

For further information, please visit:  



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

1 Year Theracryf Chart

1 Year Theracryf Chart

1 Month Theracryf Chart

1 Month Theracryf Chart

Your Recent History

Delayed Upgrade Clock